Last updated: September 4, 2026
Recombinant von Willebrand factor is marketed primarily as Vonvendi in the United States and Veyvondi in Europe. Takeda owns the commercial franchise following its acquisition of Shire, which had acquired Baxalta and the original recombinant von Willebrand factor business. The product addresses von Willebrand disease, particularly patients requiring replacement therapy without exposure to plasma-derived von Willebrand factor.
The market is commercially attractive but narrow. Demand is constrained by the relatively small diagnosed patient population, intermittent treatment in many patients, and competition from established plasma-derived products. Vonvendi’s principal strategic advantages are recombinant manufacture, high von Willebrand factor purity, absence of plasma-derived human proteins in the active product, and potential use in patients who require individualized replacement therapy. Public financial filings do not separately disclose Vonvendi revenue, so product-level sales and profitability cannot be calculated directly from Takeda’s reported results.
What is recombinant von Willebrand factor and who markets it?
Recombinant von Willebrand factor, or vonicog alfa, is a recombinant human von Willebrand factor replacement product. Von Willebrand factor supports platelet adhesion and stabilizes endogenous factor VIII. The product is administered intravenously for bleeding control and perioperative management in patients with von Willebrand disease.
| Attribute |
Information |
| Active ingredient |
Vonicog alfa, recombinant von Willebrand factor |
| U.S. brand |
Vonvendi |
| European brand |
Veyvondi |
| Original developer |
Baxalta, following earlier Shire development activity |
| Current commercial owner |
Takeda Pharmaceutical Company |
| Primary disease |
Von Willebrand disease |
| Administration |
Intravenous infusion |
| U.S. regulatory pathway |
Biologic license application under the Public Health Service Act |
| Main alternatives |
Humate-P, Wilate, Voncento, Haemate P and other plasma-derived VWF products |
| U.S. first approval |
2015 |
| Product class |
Recombinant coagulation protein |
The product is used in adults for on-demand treatment and control of bleeding and for perioperative management. Regulatory approvals and labeling differ by jurisdiction and indication. The U.S. prescribing information should control any commercial or clinical assessment of the approved population.[1]
When did Vonvendi receive FDA approval and lose exclusivity?
Vonvendi received U.S. Food and Drug Administration approval in 2015. Subsequent regulatory activity expanded the product’s clinical utility, including prophylactic treatment and additional use in surgical settings. Biologic exclusivity and patent exclusivity are separate rights.
FDA regulatory timeline
| Date |
Milestone |
| 2015 |
FDA approval of Vonvendi for on-demand treatment and control of bleeding episodes in adults with von Willebrand disease |
| 2016 onward |
Commercial expansion and post-approval clinical development |
| 2018 |
FDA approval for routine prophylaxis in adults with von Willebrand disease |
| 2018 |
European authorization of Veyvondi |
| 2019 |
Takeda completed acquisition of Shire, including the Vonvendi franchise |
Under the Biologics Price Competition and Innovation Act, a reference biologic generally receives 12 years of reference-product exclusivity from the date of first licensure. The statutory period does not automatically equal the commercial protection period because patent litigation, patent-term adjustment, pediatric exclusivity, regulatory supplements and settlement agreements can affect entry timing.[2]
For Vonvendi, the FDA approval date places the statutory reference-product exclusivity period in the late 2020s. The precise legal entry date for a biosimilar would depend on the FDA approval pathway, patent disputes, litigation outcomes and any negotiated agreement.
What patents protect recombinant von Willebrand factor?
The Vonvendi estate is expected to include several patent categories rather than a single product patent. These categories generally include the recombinant VWF molecule, production-cell systems, purification methods, formulation, and therapeutic uses.
Patent categories relevant to Vonvendi
| Patent category |
Commercial relevance |
| Recombinant VWF molecule |
Protects the engineered or expressed protein sequence and related variants |
| Host-cell and expression technology |
Covers methods for producing recombinant VWF in cultured cells |
| Purification processes |
Can protect removal of process impurities and recovery of high-purity VWF |
| Formulation |
May cover stabilizers, concentration ranges, pH and storage conditions |
| Treatment methods |
May protect dosing regimens, prophylaxis and perioperative administration |
| Manufacturing controls |
Can create practical barriers even after composition claims expire |
Biologics patent analysis requires review of U.S. patents, international patent families, patent-term adjustments, terminal disclaimers, reexaminations, post-grant proceedings and claim scope. The FDA does not publish a conventional Orange Book patent listing for biologics. Vonvendi therefore should be assessed through the Purple Book framework and direct patent records rather than an Orange Book search.[3]
Public regulatory sources do not provide a simple, consolidated list of every enforceable Vonvendi patent and expiration date. Patent expiry cannot be inferred reliably from the FDA approval year alone. A commercial launch assessment based on a single assumed expiry date would be unreliable.
What is the Orange Book and Purple Book status of Vonvendi?
Vonvendi is a biologic, so it is not analyzed through the standard small-molecule Orange Book framework. The relevant FDA reference is the Purple Book, which identifies licensed biological products and related reference-product information.
The distinction has practical consequences:
- A generic drug applicant would ordinarily rely on an abbreviated new drug application and could submit a Paragraph IV certification against listed Orange Book patents.
- A biosimilar applicant would use the 351(k) pathway.
- Patent disputes would generally arise through the biologics patent dance under the Biologics Price Competition and Innovation Act or through other patent litigation.
- Vonvendi does not have the same Orange Book listing structure as a conventional tablet or injectable small-molecule drug.
Are there Paragraph IV challenges to Vonvendi?
No conventional Paragraph IV challenge should be expected because Vonvendi is a biologic rather than an Orange Book-listed small molecule. A competitor seeking market entry would more likely pursue a biosimilar application under section 351(k) of the Public Health Service Act.
A biosimilar applicant could challenge patents through the BPCIA information-exchange process, declaratory-judgment actions, or post-grant proceedings. The absence of a public Paragraph IV filing would not establish that the product has no patent challenge risk.
No major publicly disclosed Vonvendi biosimilar litigation or settlement has established a market-entry date comparable to the well-known settlements involving major small-molecule products. The current competitive risk is therefore driven more by existing plasma-derived therapies and future biosimilar development than by an identified generic launch.
How strong is the Vonvendi patent estate?
The estate has moderate-to-strong strategic value at the product level but faces the standard limitations of biologic patent enforcement.
Factors supporting patent strength
- Recombinant manufacturing can create process claims that are difficult to design around without substantial development work.
- Product quality depends on complex expression, purification and analytical controls.
- Formulation and manufacturing patents can extend practical protection beyond the earliest composition claims.
- A biosimilar developer must demonstrate analytical similarity, clinical comparability and manufacturing consistency.
Factors limiting patent strength
- Method-of-use claims may be narrower than composition or manufacturing claims.
- A competitor may develop a non-infringing cell line or process.
- Patent claims can expire at different times, creating a staggered protection profile.
- Biosimilar applicants may challenge validity, enforceability or infringement.
- Plasma-derived VWF products do not need to copy Vonvendi’s recombinant manufacturing process.
The commercial barrier is therefore a combination of patents, regulatory requirements, manufacturing know-how and physician familiarity. Patent protection alone does not determine the product’s full competitive position.
What formulations and manufacturing barriers protect Vonvendi?
Vonvendi is supplied as a lyophilized recombinant protein that is reconstituted before intravenous administration. Product protection can extend to the formulation’s stabilizing conditions, concentration, storage requirements, reconstitution characteristics and container-closure system.
Manufacturing is a more significant barrier than formulation alone. Recombinant VWF is a large, structurally complex protein requiring controlled expression and post-translational processing. A competitor must establish:
- A suitable mammalian expression system.
- Consistent multimer distribution.
- Reliable removal of host-cell proteins and process impurities.
- Comparable potency and binding activity.
- Stable storage and reconstitution performance.
- A validated analytical package for biosimilarity.
These requirements raise development cost and increase technical risk. They also reduce the likelihood that a low-cost competitor can enter solely by duplicating the finished dosage form.
How does Vonvendi compare with plasma-derived VWF products?
Vonvendi competes with products that have longer clinical histories and established reimbursement pathways. Plasma-derived products often contain both VWF and factor VIII, while Vonvendi provides recombinant VWF and may require separate factor VIII management depending on the patient’s baseline levels and treatment objective.
| Issue |
Vonvendi |
Plasma-derived VWF products |
| Source |
Recombinant |
Human plasma |
| Product composition |
Recombinant VWF; limited or no exogenous FVIII in the finished product |
VWF with varying amounts of FVIII |
| Plasma exposure |
No plasma-derived active ingredient |
Plasma-derived |
| Clinical familiarity |
Newer product |
Long-established |
| Supply profile |
Dependent on recombinant manufacturing |
Dependent on plasma collection and fractionation |
| Competition |
Primarily specialized replacement therapy |
Broad VWF replacement market |
| Switching risk |
Requires clinician and patient acceptance |
Established treatment protocols |
| Biosimilar risk |
Potentially material over time |
More complex because products are plasma-derived and may not be interchangeable under a simple biosimilar model |
Vonvendi’s strongest commercial position is in patients for whom recombinant sourcing, product composition or individualized VWF replacement is clinically valuable. Its weaker position is in routine markets where existing plasma-derived products are reimbursed, familiar and adequate.
What is the financial trajectory for Vonvendi?
Takeda does not generally report Vonvendi as a separate revenue line in its consolidated public financial statements. The product is included within broader portfolio reporting, which prevents an independently verified calculation of annual sales, growth rate or operating margin.
Financial trajectory by phase
| Phase |
Financial characteristics |
| 2015-2018 |
Initial commercialization, limited penetration and investment in clinical adoption |
| 2018-2020 |
Expansion following additional prophylaxis and perioperative positioning |
| 2020-2022 |
Greater attention to specialized bleeding-disorder care and supply reliability |
| 2022 onward |
Mature niche biologic profile, with growth dependent on patient identification, prophylaxis adoption and geographic expansion |
The product’s revenue ceiling is limited by the size of the VWD treatment population and the fact that many patients do not require continuous replacement therapy. Revenue can still be attractive because treatment is high value, administration is specialized and severe disease generates recurring prophylaxis and surgical demand.
Key revenue drivers
- Greater diagnosis of type 3 and severe type 1 or type 2 von Willebrand disease.
- Increased use of routine prophylaxis.
- Expansion of perioperative treatment.
- Specialist-center adoption.
- Reimbursement for recombinant replacement therapy.
- Preference for products without plasma-derived active ingredients.
- Increased use in patients with poor response or intolerance to existing products.
Revenue risks
- Competition from Humate-P and Wilate.
- Restrictive reimbursement and prior authorization.
- Intermittent rather than continuous treatment.
- Hospital purchasing pressure.
- Limited product differentiation in less severe disease.
- Potential future biosimilar entry.
- Manufacturing interruptions or limited capacity.
Vonvendi is more likely to remain a strategically valuable specialty product than become a broad blockbuster. Its financial trajectory depends on price, treatment frequency and share of the severe VWD segment rather than on large-volume population growth.
What generic or biosimilar launch risks exist?
The near-term risk from a conventional generic is low because the product is a biologic. The medium- to long-term risk from biosimilars is more credible but technically demanding.
A biosimilar entrant would need to establish similarity across molecular structure, multimer distribution, functional assays, impurity profile, pharmacokinetics and immunogenicity. Interchangeability would require additional regulatory considerations in the United States. The first entrant could compete through contracting and lower net pricing even without automatic pharmacy substitution.
The most plausible launch scenario is gradual erosion rather than an immediate collapse in revenue. Specialty distributors, hemophilia treatment centers and prescribers may adopt a new product cautiously. Clinical confidence, reimbursement placement and supply reliability could be as important as list price.
Which companies compete with or could challenge Vonvendi?
The principal current competitors are manufacturers of plasma-derived VWF products:
- CSL Behring, including Humate-P and related VWF products.
- Octapharma, including Wilate and regional products.
- Grifols, including Alphanate and other plasma-derived therapies.
- Sanquin and other regional plasma-product manufacturers.
- Takeda itself, through its broader bleeding-disorder portfolio.
Potential future challengers include recombinant VWF developers, biosimilar manufacturers and companies developing gene therapy or long-acting treatments for von Willebrand disease. Gene therapy is a longer-term competitive risk because it could reduce the need for repeated replacement, but it does not represent an established direct substitute for Vonvendi today.
What litigation and settlement agreements affect Vonvendi?
No widely reported settlement agreement has created a public, defined Vonvendi biosimilar launch date. The absence of a known settlement does not remove patent risk. Potential disputes could involve:
- Recombinant VWF sequence claims.
- Cell-line and expression claims.
- Purification and manufacturing processes.
- Formulation and stability claims.
- Prophylaxis and perioperative method-of-use claims.
- BPCIA information exchange and patent-selection procedures.
A definitive litigation review requires current USPTO, FDA, PACER and international court records. Publicly reported information does not establish a material Vonvendi patent settlement comparable to major small-molecule pharmaceutical settlements.
How does Vonvendi compare with other biologic replacement therapies?
Vonvendi has a more specialized market than factor VIII or factor IX products. Hemophilia markets support larger recurring treatment populations and broader prophylaxis use. VWD is more heterogeneous, with many patients managed through desmopressin, antifibrinolytics or episodic replacement therapy.
| Market |
Treatment pattern |
Commercial implication |
| Hemophilia A |
Often recurring prophylaxis |
Larger recurring biologic market |
| Hemophilia B |
Recurring prophylaxis, increasingly long-acting |
Stronger product differentiation |
| Severe VWD |
Episodic or routine VWF replacement |
Smaller but specialized market |
| Mild or moderate VWD |
Often non-factor treatment |
Lower biologic replacement penetration |
Vonvendi’s commercial value is tied to the severe end of the VWD population, where treatment need is persistent and alternatives are less satisfactory.
Key Takeaways
- Vonvendi is the principal recombinant VWF product marketed by Takeda.
- The product received FDA approval in 2015 and later gained prophylaxis and perioperative positioning.
- It is regulated as a biologic and should be assessed through the Purple Book and BPCIA framework, not a conventional Orange Book Paragraph IV analysis.
- No public product-level Vonvendi revenue figure is reported by Takeda, limiting precise financial modeling.
- The commercial market is a specialized niche dominated by plasma-derived VWF products.
- The strongest barriers are recombinant manufacturing, quality control, clinical evidence and specialist adoption.
- Future biosimilar risk is real but likely to produce staged price and market-share erosion rather than an abrupt generic substitution event.
- Exact patent-expiry analysis requires a current family-level review of issued claims, patent-term adjustments and litigation records.
FAQs
Is Vonvendi the only recombinant von Willebrand factor product?
Vonvendi, also marketed as Veyvondi in Europe, is the leading approved recombinant VWF replacement product. Regional availability and approval status should be checked separately because regulatory approvals differ by jurisdiction.
Does Vonvendi contain factor VIII?
Vonvendi is a recombinant von Willebrand factor product and is not equivalent to plasma-derived VWF products that contain substantial factor VIII. Treatment may require monitoring and management of factor VIII levels.
Can a biosimilar automatically substitute for Vonvendi?
No. A biosimilar may be approved without being designated interchangeable. Automatic substitution depends on the FDA’s interchangeability determination and state substitution law.
Is Vonvendi used for hemophilia A?
Vonvendi is approved for von Willebrand disease, not as a standard standalone replacement therapy for hemophilia A. Its VWF activity can affect factor VIII stability, but hemophilia A treatment follows separate regulatory indications and clinical protocols.
What is the main investment risk for Vonvendi?
The principal risks are limited market size, undisclosed product-level financial performance, competition from established plasma-derived products, reimbursement restrictions and eventual biosimilar or next-generation replacement therapy.
References
- U.S. Food and Drug Administration. (2023). Vonvendi (vonicog alfa) prescribing information.
- U.S. Food and Drug Administration. (2024). Reference product exclusivity and biosimilar development under the Biologics Price Competition and Innovation Act.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- Takeda Pharmaceutical Company Limited. (2024). Integrated report 2024.
- European Medicines Agency. (2018). Veyvondi: EPAR product information.
